Page last updated: 2024-12-05

4-nitrophthalimide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-nitrophthalimide is a yellow crystalline solid that is commonly used as a precursor in the synthesis of various organic compounds. It can be prepared through nitration of phthalimide. 4-nitrophthalimide has been investigated for its potential applications in the fields of pharmaceuticals, materials science, and organic electronics. Its electron-withdrawing nitro group and its ability to form N-heterocyclic carbene complexes make it a valuable reagent in organic synthesis. The compound also exhibits fluorescence properties, which have been studied for its use in sensors and other optical applications. Further research is ongoing to explore its full potential in various fields.'

4-nitrophthalimide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6969
CHEMBL ID1607202
SCHEMBL ID151957
SCHEMBL ID16303093
MeSH IDM0219112

Synonyms (60)

Synonym
phthalimide, 4-nitro-
nsc-5394
nsc5394
1h-isoindole-1, 5-nitro-
4-nitrophthalimide
89-40-7
1h-isoindole-1,3(2h)-dione, 5-nitro-
AE-641/30105047
5-nitro-1h-isoindole-1,3(2h)-dione
5-nitroisoindoline-1,3-dione
OPREA1_866451
NCGC00091620-01
5-nitrophthalimide
einecs 201-905-5
brn 0180224
ai3-00701
nsc 5394
ccris 4685
4-nitrophthalimide, 98%
STK397451
AC-10997
AKOS000313129
5-nitroisoindole-1,3-dione
N0247
A843189
NCGC00091620-02
unii-26na19ui3u
26na19ui3u ,
5-21-11-00158 (beilstein handbook reference)
cas-89-40-7
dtxcid405776
tox21_200190
NCGC00257744-01
dtxsid1025776 ,
F0345-4666
5-nitro-2,3-dihydro-1h-isoindole-1,3-dione
FT-0619295
CHEMBL1607202
SCHEMBL151957
5-nitro-isoindole-1,3-dione
5-nitro-phthalimide
SCHEMBL16303093
5-nitro-1h-isoindole-1,3(2h)-dione #
4-nitro-phthalimide
W-100375
mfcd00005884
sr-01000397641
SR-01000397641-1
AS-9405
D70991
CS-W023085
Z56812733
5-nitroisoindoline-1,3-dione;5-nitro-1h-isoindole-1,3(2h)-dione;phthalimide, 4-nitro-
BCP30589
SY039319
AMY272
Q27254119
SB64042
3-buten-2-ol, 1,1,1-trifluoro-2-(trifluoromethyl)-
EN300-16888
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency56.23410.004023.8416100.0000AID485290
GLI family zinc finger 3Homo sapiens (human)Potency77.58540.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency5.54250.000221.22318,912.5098AID743036
pregnane X nuclear receptorHomo sapiens (human)Potency61.62820.005428.02631,258.9301AID1346982
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency24.75760.001019.414170.9645AID743191
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency39.23810.057821.109761.2679AID1159526
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency69.14800.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency53.56690.000627.21521,122.0200AID743202; AID743219
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID660254Inhibition of bovine xanthine oxidase assessed as uric acid formation using xanthine as substrate at 100 uM after 30 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.
AID659106Competitive inhibition of Vibrio cholerae ASADH using aspartyl semialdehyde as substrate by Dixon plot analysis2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Molecular docking and enzymatic evaluation to identify selective inhibitors of aspartate semialdehyde dehydrogenase.
AID659105Competitive inhibition of Streptococcus pneumoniae ASADH using aspartyl semialdehyde as substrate using Dixon plot analysis2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Molecular docking and enzymatic evaluation to identify selective inhibitors of aspartate semialdehyde dehydrogenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.80 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]